According to the results, approximately 70% indications of BTK inhibitors analyzed in this study were lymphocytic malignancies (Chronic lymphocytic leukaemia, mantle cell lymphoma and waldenstrom’s macroglobulinaemia ranked the top three indications of the two BTK inhibitors induced AEs), which was also in accordance with the clinical practice. This evidence concerns the gene BTK and Waldenstrom macroglobulinemia.